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The original extraction procedure of Engel and Catchpole [1] has often been used to recover decorin-enriched material from the skin.
This material has a strong inhibitory eﬀect on ﬁbroblast proliferation, and clearly suppre s s e si ti ns k i ne x c e p ta f t e rt h eﬁ r s t5 – 6d a y s
of wounding when new scaﬀold material is required. The aim of our present study has been to ﬁnd and evaluate the product of a
faster recovery method, and to check its consistency as a more reliable means of regularly obtaining suﬃcient material for topical
application in wounds that might become hypertrophic. Modiﬁcations of the original Toole and Lowther [2]e x t r a c t i o np r o c e d u r e
havebeencarefullyevaluatedinanattempttocutpreparationtimewithoutcompromisingbiologicalactivityoftheinhibitoryextract.
We have devised a faster recovery procedure without compromising biological activity, even if initial recovery has been somewhat
reduced. The latter problem could be oﬀset by repeated cycles of the ﬁnal extraction step. The main inhibitory activity is shown to be
within the decorin-enriched “extract D,” as the core protein and DSPG II. Adjustment of the extract towards neutrality after dialysis
against water keeps most of the extracted protein in solution and yielded a decorin-enriched preparation that had a speciﬁc activity
equivalent to that of the old method. It also yielded a fraction that was readily lyophilised to give a small amount of material that
could be stored indeﬁnitely without loss of activity and readily redissolved in aqueous solution. A reliable and relatively quick method
is presented for the production, from human skin, of a decorin-enriched preparation that has strong ﬁbroblast inhibitory action. The
value of the procedure is that it is inexpensive and can produce the quantities that might be used topically in reducing hypertrophic
scarring of wounds.
BACKGROUND
Our aim is to extract the natural inhibitor of ﬁbrob-
last proliferation, decorin, from human skin [3]. Decorin
is a 118kd proteoglycan (DSPG-II) that aﬀects ﬁbroblasts
by arresting proliferation, slowing their migration and re-
ducingtheirabilitytocontractcollagengels[4,5].Itinter-
acts with TGF-β1 to modify its responses in both normal
and injured skin [6].
Decorin is available commercially both of bovine and
of human origin, but is very expensive. Engel and Catch-
pole’s procedure [1], based on that of Toole and Lowther
[2], has routinely been used to recover the inhibitory
principle, but it is labour-intensive, time-consuming, and
sometimes hazardous because it involves the cooling of a
Culatti mill with liquid nitrogen. Most extracts, namely,
A, B, C, and E, have been of little interest in wound heal-
ing, with only D being of value. We therefore tried to pro-
cure extract D more quickly.
There are many other methods for extracting decorin,
and skin has been a less regularly used source than
other human tissue (eg, articular cartilage [7]), as well
as cartilage and muscle from bovine species [8, 9].
These methods have used extraction procedures that
could be quickly adapted to ion-exchange columns, gel
chromatography, and density gradient centrifugations
for qualitative studies. The use of 4M guanidine hy-
drochloride in articular cartilage is a standard procedure
http://bssv01.lancs.ac.uk/gig/pages/pg/smallpgs.htm,b u t
it should be noted that many of these procedures for
identiﬁcation and characterization of decorin in qualita-
tive terms are not speciﬁcally geared to recovering suﬃ-
cient yields of native decorin for application in clinical
studies. The problem of species diﬀerences arises, al-
though decorin from all these sources seems to have sim-
ilar inhibitory capacities (see below). With regard to the
original system of Toole and Lowther [2], the operating
costs in terms of time were high, but materials were rel-
atively inexpensive. With these considerations in mind,
our main objective has been not only to speed up ex-
traction, but also to retain adequate speciﬁc activity of
the decorin-enriched extract D, while at the same time
obtaining yields from fresh human skin that could po-
tentially be used in clinical application and not just for212 Denys N. Wheatley et al 2004:4 (2004)
Figure 1. Immunoﬂuorescence micrograph of a section of hu-
man skin stained with FITC using anti-decorin as the primary
antibody(see“materialsandmethods”).Theepidermisfallsinto
two parts, with the outer more corniﬁed cells showing some
nonspeciﬁc labelling (small arrow), whereas the main part of
the epidermis is essentially devoid of staining (large arrow). The
dermis is well delineated and is progressively richer in decorin
towards its internal aspect (star). Original magniﬁcation ×240.
molecularcharacterisation.Sincethispaperconcernspro-
cedural matters, the “materials and methods” section will
be dealt with up front.
MATERIALS AND METHODS
Skin was obtained at operations of normal female pa-
tients undergoing either breast reduction or abdomino-
plasty, with 10 patients being involved, each having given
their consent for the operation and the use of their skin in
this speciﬁc research project. Full ethical permission was
obtained from the local committee for this work. The av-
erage age was 35 years, ranging from 25 to 67. After the
operation, the skin was placed in a sterile container and
cooled to refrigeration temperature before being collected
and used. The time lapse was usually almost 60 minutes,
although on 3 occasions it was overnight (16–20 hours)
without signiﬁcant loss of biological activity.
Step1
The pieces of skin varied from about 9 to 40g, a suit-
able size to handle for each preparation being of almost
20g wet weight. They were washed free of blood in ice-
coldisotonicsalinebeforeandafterbeingpinnedout,epi-
dermal side down, on a Teﬂon board set into crushed ice.
Fat was removed as quickly as possible, after which the
surface of the skin was scraped with a solid metal scalpel,
andthedermalmaterialplacedinacleanpreweighed200-
mL Erlenmeyer ﬂask, this being the richest in decorin
(Figure 1). (No attempt was made throughout this work
to remove the epidermis. Since it is deﬁcient in decorin, it
was not worthwhile spending time removing it at the start
of the preparation.) The remaining skin was horizontally
scored into ﬁne strips with a disposable “C” blade scalpel,
Fat removed from skin
Whole skin sliced very thinly
into slivers on ice
Rinsed 3 times in 200mL DDW
Extracted with 1M NaCl
3c h a n g e so v e r1 8ha t4 ◦C
Residue extracted with 1M citric acid/citrate buﬀer
(pH 3.5) 3 changes over 18h at 4◦C
Supernatant from “D” dialysed against
3 changes of ultrapure water over 18h
Alternatively, dialysate ﬁltered
(0.45µm) and lyophilised
over 18h
Frozen at −20◦C
Residue
reextracted
Dialysate ﬁlter-sterilised,
assayed, and used
Approximate
hours
0.5
1.0
2.0
20.0
38.0
56.0
74.0
Schema 1. Preparation of human dermal extract D.
followed by slicing at 90 degrees to release thin slivers of
skin.ThesliverswereputintotheErlenmeyerﬂask,which
was reweighed to give the ﬁnal amount of skin to be ex-
tracted.OnehundredmLofice-coldwaterwasaddedand
the material swirled for 10 minutes; this process was re-
peated twice. This was followed by a similar operation
with ice-cold 0.15M saline before the skin material was
collected on a wire mesh.
The procedure thereafter followed the ﬂow diagram
given in Schema 1, and the following steps (see below) in-
dicate most of the important modiﬁcations used in reach-
ing this ﬁnal protocol after many trials. The conventional
method of extract D preparation by Toole and Lowther
[2] took at least 11days, whereas the present procedure
can reach the same stage in 56 hours without the yield of
decorin being substantially reduced.
Step2
Skin material was put into 100mL ice-cold 1M NaCl
to which 0.5mL saturated phenylmethylsulphonylﬂuo-
ridesolutionwasadded(PMSF,Sigma,PooleDorset,UK)
(but not on all occasions), and the ﬂask swirled at 4◦Cf o r
18 hours, with changes at 1 hour and 3 to 4 hours.
Step3
The skin pieces were collected in a mesh and pressed
to remove the salt solution before being placed in 100
mL 1M citrate buﬀer (pH 3.5 )t ow h i c hP M S Fh a db e e n
added as above. The ﬂask was swirled at 4◦C for 18 hours,
at which time the material was separated into solid and2004:4 (2004) Accelerated Decorin Extraction From Human Skin 213
supernatant fractions by passing the preparation through
a ﬁne steel mesh. The latter was called extract D. The solid
residuumwastakenonceagainthroughStep3,thesecond
extract being DD, the third DDD, and so on.
Step4
Supernatant from Step 3 was put into 5 dialysis
bags each containing almost 20mL extract, and dialysed
against three changes of 5 L dialysand—using a variety
of diﬀerent solutions for comparison of eﬃcacy—for not
less than 20 hours total.
Step5
The dialysed extract was put through a 0.45µ Sarto-
rius ﬁlter, set out in 20mL aliquots in preweighed ster-
ile containers some was set aside for immediate assay of
protein and gel electrophoresis, while the remainder was
freeze-dried. The latter material was kept in at −20◦Cu n -
til required, and then reconstituted in a medium without
serum to the desired concentration to treat cultures (see
below), or in water for protein assay, electrophoresis, and
other analyses.
Cellculture
Human diploid ﬁbroblasts growing in RPMI 1640
with 10% fetal calf serum were used for growth studies.
They were from several diﬀerent patients (given by diﬀer-
entinitials—SMIF,JMF,andRWF),althoughcomparison
was also made with a fetal foreskin culture, FF/9. A frozen
bankofeachculturewaskeptatpassage6andusedwithin
one or two subcultures from this stock in each case.
Cells were seeded at 50000 cells per well in 12-well
plates. Growth was followed by two procedures as de-
scribed previously [3], either trypsinization followed by
dispersal and counting electronically in a Coulter counter,
or daily estimates of cells by direct phase-contrast mi-
croscopy within a designated set of 6 squares on the bot-
tom of each dish. For this latter procedure, cells were nor-
mally set out in 25cm2 ﬂasks.
Otherprocedures
Lyophilised extract D was dissolved in water before
being adjusted to normal medium strength by the addi-
tion of one-tenth volume of 10 times concentrated RPMI
1640 solution. The solution was ﬁlter-sterilised through
a0 .45µm Sartorius ﬁlter and introduced at the required
volumetoculturesofknownproteincontent(µgpermL).
Electrophoresis of samples was undertaken precisely
as described in our previous paper using a conventional
silver staining technique to show up the weak bands [4].
Immunochemical staining for decorin was carried out on
6t o7 µm frozen skin sections stained with antidecorin
(1 : 5 dilution) as primary, FITC-conjugated anti-rabbit
polyclonal antibody (1 : 20 dilution) as secondary, as de-
scribed in [10].
200
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Figure 2. Gel electrophoresis of extracts, as described in “ma-
terials and methods” and [4] on 3%–20% gradient gels, with
3% stacking gel. The left lane is a kaleidoscope MR marker for
decorin with stated values to its left. The lanes are 1, skin B ﬁrst
extract(D);2,skinBsecondextract(DD);3,skinBthirdextract
(DDD); lane 5 is authentic decorin; lanes 6–8 are as 2–4, but for
skin C; silver staining.
RESULTS
Rapidprotocol
Aftermanydiﬀerentvariationsoftheprocedure,often
as a series on pieces of skin from the same patient or, on
other occasions, using pieces from diﬀerent patients, we
slowly moved towards the best way of obtaining adequate
amounts of decorin in extract D. The following three cri-
teria were used to assess the product: (a) total soluble pro-
tein extracted, (b) its inhibitory activity against ﬁbroblast
proliferation in vitro, and (c) the presence of the appro-
priate bands on gels at 45 and 115–120kd [4]( Figure 2).
Much of this work will be summarised, with little data
from negative or ineﬀective trials being included where
no beneﬁt was gained or a poor yield resulted. Between
15 and 20 separate trials were completed, usually giving
a progressively better performance. In many cases, skin
specimensweredividedintotwoparts,onegoingthrough
the best extraction procedure to date and the other be-
ing subject to the next modiﬁcation of the protocol. In
one experiment, a 90-g piece of skin was divided into 3
approximatelyequivalentpartsforseparateextractionsby
the latest protocol to check the consistency of the pro-
cedure. The preparations were almost identical in every
respect, except for a slightly smaller yield from the ﬁrst
piece, indicating that the extraction procedure was rela-
tively reliable and consistent (Figure 3a).
Generalremarks
The following annotations give some guidance to the
seriesofexperimentsthatleadtotherapidextractionpro-
cedure.
Sterility was not strictly adhered to throughout the
procedures. However, careful measures included to min-
imise the risk were keeping skin cold from the time of col-
lection,undertakingthepreparationinasterilehood,and
using ice-cold sterile saline or phosphate buﬀered saline
(PBS) for washing the material 3 times. Sterility of the
product at the end of the protocol was ensured by extracts
being ﬁlter-sterilised before use on cells for testing their
inhibitory activity.214 Denys N. Wheatley et al 2004:4 (2004)
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Figure 3.Yieldsinmicrogrammesofproteinfrom3separatepiecesofthesamesampleofhumanskinshowingtheconsistentrecovery
of protein in extract D, each piece having a wet weight of almost 13g. The bars show the mean ±1 SD of the average protein estimate
of 4 determinations.
Table 1. Recovery of proteins in extracts from three separate pieces of the same skin treated in identical manner.
Skin
Wet weight
(mg)
P r o t e i ni ne x t r a c t
D( m g )
P r o t e i ni ne x t r a c t
DD (mg)
Protein in extract
DDD (mg)
Sample 1 13900 10.46 .62 .4
Sample 2 14200 (7.1)∗ 7.22 .7
Sample 3 12400 13.07 .81 .9
Average ± 1 SD 13500 ±960 11.77 .2 ±0.62 .3 ±0.3
P r o t e i ni nm g / gs k i n — 0 .87 0.37 0.17 (total = 1.41)
∗∗Estimated decorin content (µg)/g skin — 78 33 19 (total = 130)
∗Some extract accidentally lost during preparation.
∗∗Assuming almost 9% of mass is decorin (see text).
PMSF was added in the ﬁrst 7–8 skin preparations.
Gelsanalysedforsmearingfollowingprocedureswithand
withoutPMSFshowednodetectablediﬀerence,andyields
were also unaﬀected. Activity of the extracts against ﬁ-
broblast was no diﬀerent whether PMSF had been used
or not. Since PMSF has noxious properties above the con-
centration we used (ie, a 200-fold dilution of a saturated
solution in water), it was deemed safer to leave it out.
Early extractions were simpliﬁed over a period of 4
separate preparative runs. The initial skin washings were
important to free blood and other unwanted material
for the preparations. Extractions in water and normal
saline (0.15M NaCl)—which yielded extracts A and B in
theoriginalprocedure—wereeventuallyreducedtoabout
half an hour each without much noticeable eﬀect on the
protein concentration or activity of extract D recovered.
It seemed that the quicker the pieces of skin reached 1M
NaCl for extraction overnight the better, although leaving
out these earlier steps altogether was not entirely satisfac-
tory. The overnight extraction with 1N NaCl was neces-
sary to remove much collagen and unnecessary proteina-
ceous material, and was an important step that could not
be omitted without considerable loss of recovery of good
speciﬁc activity decorin. However, a time-course analysis
should, for optimal eﬃcacy, be how long 1N NaCl ex-
t r a c t i o ns t i l ln e e d st ob ec a r e f u l l yc o m p l e t e d .T h es e c o n d
overnight extraction with citrate buﬀer at pH 3.5 was the
crucial step.
Repeated extraction with citrate buﬀer answered the
questionastowhetherasingleextractionperiodofalmost
20 hours released signiﬁcant amounts of or most of the
decorin. In brief, the initial overnight extraction with cit-
rate buﬀer was sometimes almost as good as the original
method of Toole and Lowther [2], but we found that skin
(the second column of Figure 3a) yielded further decorin
on the second and third extraction cycles (Figure 3b), al-
though the yield was considerably reduced each time. To
maximisereleaseatthesecondandthirdextractioncycles,
we extended these extraction periods to 72 hours, but it
did not signiﬁcantly increase the overall yield. Details for
the sequence of extractions have also been summarised in
Table 1. The second and third extracts (DD and DDD)2004:4 (2004) Accelerated Decorin Extraction From Human Skin 215
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Figure 4. Graphs showing the ability of the three skin extracts
D shown in Figure 3 to inhibit fetal ﬁbroblasts (FF) growth. The
assay was made after 3 days growth and records the increase
in cell number relative to the control (100% at 0 extract). The
amount of extract represented in the added volumes was ∼50
µg per mL. The symbols refer to:  extract 1;  extract 2; ◦
extract 3;• pure decorin. The values are means of 4–6 determi-
nations at each point, ± 1 SD. (Where bars are not evident, they
lie within the symbols.) Note that at low concentration, decorin
has no stimulatory eﬀect on cell growth.
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Figure 5.ReleaseofextractDfromhumanskinfollowingapro-
longed incubation with a single batch of the citrate buﬀer. The
curve demonstrates the protein recovery, which is related closely
with its antiﬁbroblast activity. More than half the maximal ex-
traction at 400 hours was achieved within the ﬁrst 60 hours.
Time points are single values taken from a single extraction pro-
cedure.
also gave very similar ﬁbroblast inhibition on a speciﬁc
activity basis, but one notable diﬀerence was the slightly
higher stimulatory eﬀe c to ft h eﬁ r s te x t r a c t( e x t r a c tD )
compared with the second and third extracts (Figure 4).
Ac o n t i n u o u se x t r a c t i o nf o rm o r et h a n2w e e k sw a su n -
dertaken (Figure 5), without the extraction buﬀer being
changed throughout this period. This showed that rapid
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Figure 6. Total extract D from an incubation using the short
protocol. The extract was dialysed in 0.15N NaCl, and the
protein recovery measured in the supernatant (supnt) and in
the material that precipitated out during the dialysis (residue).
These both retained decorin-like activity, as shown in Figure 7.
e x t r a c t i o no c c u r r e df o r5 0t o6 0h o u r s ,b u tt h e r e a f t e ra c -
cumulation of active extract was much slower. Indeed,
between a third and a half of the maximum extraction
was released with an 18–20 hour single overnight extrac-
tion, if a compromise between yield and extraction time
is sought.
Dialysis was carried out against a range of diﬀer-
ent dialysing solutions to see whether this improved re-
covery. Saline, PBS, and water, with or without EDTA
(0.1m M ) ,h a v ea l lb e e nu s e d .I nb r i e f ,w a t e rp r o v e dt h e
best dialysand, as in the original method. Addition of
EDTA made no diﬀerence. When the pH remained be-
low 4.2 in a salt-containing dialysand, a ﬂocculent pre-
cipitate invariably developed comprising about half the
total protein of extract D (Figure 6). This was removed
by ﬁltration through a 0.2µM ﬁlter, and the ﬁltrate ad-
justed to neutrality with a small amount of 1N NaOH.
The residuum was resuspended in water and adjusted
to neutrality, which resulted in all but 8%–14% of the
total protein redissolving (see Table 1). Analysis of the
two fractions on the ﬁbroblast proliferation inhibition
assay showed that both had similar speciﬁc activities in
their inhibitory action on ﬁbroblasts (ie, per µg protein;
Figure 7).
Water was in the end preferred for dialysis; a 20mL
volume of extract D dialysate increased to 23mL, with
negligible contamination with salts. Dialysis against
0.15N NaCl, in comparison, increased the volume of ex-
tract D to barely 21.3mL, with the salt content equili-
brating at almost 12 mg/mL, but with much heavier pre-
cipitation of protein that was more diﬃcult to redissolve
when the pH was adjusted to neutrality. The lack of salt
in the former dialysate meant lyophilisation gave an ex-
tremely small residue of dirty whitish (sometimes slightly
brownish) ﬂuﬀy “glass,” which readily redissolved in wa-
ter or any other medium at the desired concentration.
Lyophilisation of extract with salts in the dialysand gave
a voluminous white residue that readily redissolved in
aqueous solution.216 Denys N. Wheatley et al 2004:4 (2004)
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Figure 7. Inhibition of ﬁbroblast growth by extract as super-
natant ()a n dr e s i d u e( ), as shown in Figure 6.T h ev a l u e s
are means of 4–6 determinations per time point ± 1S D .
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Figure 8. Lowry’s analysis of preparations made on a mass basis
(nominally taken as protein) and plotted against the colorimet-
ric assay. Bovine serum albumin (BSA) is taken as a standard
and is plotted as a straight-line correlation of 1 (). Authentic
decorin (•) is considerably below this line, indicating that its
massasaproteoglycanisunderestimatedbytheLowryassay.On
the basis of protein relative to glycosaminoglycan in decorin (ie,
118/45kd), the curve (◦) has been plotted, which now indicates
an overshoot in estimation. Hence by inference, the preparation
will be in core protein rather than the full-size proteoglycan (see
Figure 3).
Protein recovery for extract D was usually in the range
of0.75–1.5mgpergramofskin(Table 1;cf[7]).However,
the actual mass of decorin molecules could have been un-
derestimated by 60%–70% by Lowry’s analysis because
of the relative size of the glycosaminoglycan side chain
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Figure 9. Eﬀect of an extract D preparation on 4 diﬀerent hu-
man ﬁbroblast primary cultures, three from adult patients (JM,
RW, and SMI) and one culture of fetal ﬁbroblasts (FF). The bars
plot the ID50 in terms of the volume in microlitres of extract
added, each having been prepared to the same mg per mL prior
to the start of an incubation for 3 days before estimation. The
dark bars show extract from the rapid extraction procedure, and
the grey bars show extract from the old procedure. The vari-
ation in sensitivity of cell lines around mean ID50 of approx-
imately 60µL is relatively small, although JM ﬁbroblasts were
clearly more sensitive to both preparations.
(Figure 8) that does not contribute to the protein assay.
The exact amount of decorin cannot therefore be deter-
mined easily and directly simply by measuring protein
yield. Our estimation was carried out biologically, on the
basis of relative inhibitory activity against a bovine artic-
ular decorin standard (almost 88% pure) from Sigma. It
assumed no stimulant eﬀect of extract D having to be oﬀ-
set by its decorin content, and yet clearly it can be seen
from Figure 8 that this also gives an underestimate. The
decorin yield averaged 9% of the total yield, with a range
of from almost 5 to a maximum of 12%–13% (Table 1).
Lowry’s analysis of several simultaneous preparations
showed that in a typical preparation of each type, the
original method yielded an extract with more protein
(almost 70µg/mL), whereas our rapid extraction yielded
less (almost 45–50µg/mL). In terms of inhibitory activ-
ity, as seen from Figure 9, the rapid extraction method
gave a consistently weaker response over three days of
inhibition, assessed on the IC50 at this time on the four
diﬀerent batches of human ﬁbroblasts tested, and the two
procedures were not at variance by more than 10%–15%
in total yield of active compound. Therefore, in terms of
overall recovery of decorin, the compromise was about
20%–30% on the original procedure for a saving of some
8daysormoreinrecoverytime.
DISCUSSION
The rapid extraction process usually yields less pro-
tein butgivesa better dose response curve, suggesting that
therapidextractionprocessisbeingslightlymoreselective
for the active compound, or possibly that speeding up the
overall process preserves more active molecules than the2004:4 (2004) Accelerated Decorin Extraction From Human Skin 217
old methods [1, 2]. It has been impossible to estimate loss
of activity during preparation, but it is signiﬁcant and is
unlikely to be due to proteolysis, since inclusion of PMSF
throughout the process made no signiﬁcant diﬀerence to
recovery, and was therefore omitted. Keeping prepara-
tions cool was enough to maintain activity of decorin,
which is a relatively stable molecule.
T h en e we x t r a c t i o np r o c e d u r ei sn o tr a d i c a l l yd i ﬀer-
ent from the original one, but essentially leaves out un-
necessarystepsorreducesthemtotheshortestconvenient
time. However, the exercise was necessary to show that it
could be done quickly without totally compromising the
recovery of a decorin-enriched fraction, and also to test
its reliability and reproducibility (Figures 3 and 9). From
the re-extraction work (Figure 5), it appears that a con-
tinuous automated recovery protocol could be adopted to
leach out as much decorin as possible over a period of
a b o u taw e e kw h e r et i m ei sn oo b j e c t .
Theproductcanbelyophilisedandreadilyredissolved
i nw a t e r ,P B S ,o ra n yo t h e rm e d i u mi no r d e rt ot r e a tc u l -
tures. A slight enhancement of ﬁbroblast growth was con-
sistently seen at low concentrations, but has never once
been found with “pure” decorin preparations. It follows
that the stronger stimulatory eﬀe c ta tl o wd o s e si sd u et o
an impurity that operates at low concentration on cells,
and that its eﬀect must be overridden by decorin itself as
concentration increases. Therefore if our decorin-rich ex-
tract were further puriﬁed to free itself of the stimulant, it
would show a slightly higher inhibitory action than indi-
cated from our present data.
We have not regularly taken our preparations through
further puriﬁcation here, but continuous extraction fol-
lowed by fractionation as described in [4] on a prepara-
tive scale will yield a considerable amount of high-activity
decorin from human skin. The amount of decorin is con-
siderable when one considers that its main function is
probably to repress the action of TGF-β. Decorin is a low-
aﬃnity high-capacity inhibitor in this respect, but the ev-
idence suggests that it may have other properties yet to be
discovered (see below).
Comparison of our preparation has so far been made
against bovine decorin recovered at a purity of almost
88% from articular cartilage. This may not be a fair
comparison with the human skin proteoglycan, since the
core protein may not be entirely homologous and the
glycosaminoglycan chain associated with it might diﬀer.
However, both are inhibitory, so there has to be at least a
close “physiological” homology. There has also been the
need for authentic human decorin as a standard. More re-
cently, EMP Genetech (Denzlingen, Germany) and R&D
Systems Europe Ltd (Abingdon, UK) have marketed hu-
man recombinant decorin of improved purity (more than
95%), but at costs that are substantially higher than the
Sigma bovine preparation, and these new products have
yet to be tested in our laboratory. Once again, these ex-
pensive products are ﬁnancial disincentives to the use of
decorin preparations for wound treatment in clinical tri-
als, whereas our method provides a plentiful and cheap
source of the natural human product that, applied topi-
cally, might well be in clinical use in the near future.
In a following report, we will include comparisons of
activities of some of these preparations on the following
systems:ﬁbroblastsgrowthwithandwithoutTGF-βtreat-
ment,melanomacells,andinvitroangiogenesis.Thisisin
keeping with the clear-cut evidence that decorin might be
useful in other theatres of action, for example, in cancer,
and not just in wound healing [11, 12].
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